HER2阳性转移性乳腺癌治疗年度进展  

Annual progress of HER2 positive metastatic breast cancer

作　　者：柴洁[1] 姚和瑞[1] CHAI Jie;YAO Herui(Breast Tumor Center,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,China)

机构地区：[1]中山大学孙逸仙纪念医院乳腺肿瘤中心,广州510120

出　　处：《岭南现代临床外科》2018年第2期123-127,132,共6页Lingnan Modern Clinics in Surgery

基　　金：国家自然科学基金(81372819;81572596;U1601223);广东省自然科学基金(2017A030313828);广州市科技计划(2014J4100170;201704020131)

摘　　要：乳腺癌是我国女性发病率最高的恶性肿瘤,其中HER2阳性转移性乳腺癌在晚期乳腺癌占比为25%~30%。HER2阳性乳腺癌患者预后差,如何提高HER2阳性转移性乳腺癌的治疗效果,包括优化靶向治疗、化疗药物的选择、后线治疗的策略等具有重要的临床意义。本文基于2017年各大乳腺癌会议,针对HER2阳性转移性乳腺癌在临床中的常见问题,阐述HER2阳性转移性乳腺癌治疗策略的新进展。Breast cancer is one of the most common malignant disease in China.HER2 positive meta-static breast cancer accounted for 25%to 30%.The prognosis of HER2 positive metastatic breast cancer is poor,how to improve the therapeutic effect of HER2 positive metastatic breast cancer havevitalclinical-significance,including optimize targeted therapy,selection of chemotherapy and strategy beyond first-line therapy.This article based on the 2017 breast cancer conference and reviewed thelatestprogress of HER2 positive metastatic breast cancer.

关 键 词：HER2阳性 转移性乳腺癌 靶向优化 年度进展 

分 类 号：R737.9[医药卫生—肿瘤]